---
figid: PMC5362545__oncotarget-08-16052-g001
figtitle: 'Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the
  current landscape and barriers to clinical application'
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Human papillomavirus
- Mycobacterium tuberculosis variant bovis BCG
- Theobroma cacao
- NA
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC5362545
filename: oncotarget-08-16052-g001.jpg
figlink: /pmc/articles/PMC5362545/figure/F1/
number: F1
caption: The FGFRs dimerize upon ligand binding and trigger a downstream cascade of
  signaling pathways. The FGFR receptors (1-4) can become activated by mutation, translocation,
  or gene amplification. An increase in circulating FGF ligands can also cause activation.
  Downstream signaling can trigger the mitogen activated protein kinase (MAPK) pathway,
  the phosphoinositide-3-kinase (PI3K/Akt) pathway, the phosphorylation of the signal
  transducer and activator of transcription (STAT), and the PLCγ activation of the
  DAG-PKC and IP3-Ca2+ cascade resulting in DNA transcription. Negative feedback loops
  can attenuate the signaling cascade at varying levels. As seen above, the “similar
  expression to FGF” (SEF) family members can interact with the cytoplasmic domain
  of FGFRs and inhibit downstream signaling. It is hypothesized that FGFRL1 (atypical
  receptor/FGFR5) may serve as a ligand trap, may dimerize with other transmembrane
  FGFRs and inhibit autophosphorylation, or may increase turnover rates of other FGFRs
  []. No evidence exists for these mechanisms.
papertitle: 'Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the
  current landscape and barriers to clinical application.'
reftext: Young Kwang Chae, et al. Oncotarget. 2017 Feb 28;8(9):16052-16074.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9737322
figid_alias: PMC5362545__F1
figtype: Figure
redirect_from: /figures/PMC5362545__F1
ndex: 644d71a8-dec2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5362545__oncotarget-08-16052-g001.html
  '@type': Dataset
  description: The FGFRs dimerize upon ligand binding and trigger a downstream cascade
    of signaling pathways. The FGFR receptors (1-4) can become activated by mutation,
    translocation, or gene amplification. An increase in circulating FGF ligands can
    also cause activation. Downstream signaling can trigger the mitogen activated
    protein kinase (MAPK) pathway, the phosphoinositide-3-kinase (PI3K/Akt) pathway,
    the phosphorylation of the signal transducer and activator of transcription (STAT),
    and the PLCγ activation of the DAG-PKC and IP3-Ca2+ cascade resulting in DNA transcription.
    Negative feedback loops can attenuate the signaling cascade at varying levels.
    As seen above, the “similar expression to FGF” (SEF) family members can interact
    with the cytoplasmic domain of FGFRs and inhibit downstream signaling. It is hypothesized
    that FGFRL1 (atypical receptor/FGFR5) may serve as a ligand trap, may dimerize
    with other transmembrane FGFRs and inhibit autophosphorylation, or may increase
    turnover rates of other FGFRs []. No evidence exists for these mechanisms.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Hspg2
  - ras
  - Hras
  - Kras
  - Rem1
  - Frs2
  - Zhx2
  - Grb2
  - Mdk
  - Pik3r1
  - Akt1
  - Il17rd
  - Fgfrl1
  - Sdc1
  - Sdc2
  - Pik3cg
  - Prkcg
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - HSPG2
  - SDC2
  - KRAS
  - HRAS
  - NRAS
  - XYLT2
  - SOS1
  - SOS2
  - FRS2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - GRB2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - AKT1
  - AKT2
  - AKT3
  - TFCP2
  - IL17RD
  - btl
  - htl
  - bnl
  - Gclm
  - Ras64B
  - Ras85D
  - Sos
  - Raf
  - drk
  - Dsor1
  - Mtk
  - Stat92E
  - MKP-4
  - p38b
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Akt
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
